Pharmacy Times

JANUARY 2, 2024

Patients who receive stimulation at different parts of the brain may reap benefits.

177

177

STAT

JANUARY 2, 2024

AUSTIN, Texas — Eleven years ago, local officials promised voters in the most liberal county in Texas that if they supported tens of millions of dollars in new taxes, they’d deliver a win-win scenario: Austin would get a new medical school, and poor people navigating the health care system in a state with the country’s worst uninsured rate would get more health care services.

Medical Schools 145

Medical Schools Hospitals 145

Pharmacy Times

JANUARY 2, 2024

The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.

Immunization 148

Immunization 148

Fierce Pharma

JANUARY 2, 2024

On the heels of a major Paxlovid inventory write-off in the United States, many more doses of Pfizer's COVID-fighting antiviral are going to waste overseas. | At the end of November, more than 1.5 million courses of Pfizer’s Paxlovid had expired unused in European countries, analysts at Airfinity said in a new report. The total tally of expired doses in Europe is expected to hit 3.1 million by the end of next month, representing a value of $2.2 billion.

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JANUARY 2, 2024

Real-world data can help resolve access barriers by providing a highly detailed view into the barriers that impact specific patient populations.

143

143

STAT

JANUARY 2, 2024

The  blue muffin challenge. Food sensitivity tests. Microbiome test kits. Self-help gastrointestinal health is all the rage. Rightly so: One in four Americans is affected by digestive disorders. And we’re all eating worse, sleeping less, and experiencing more stress , leaving our guts feeling twisted.

140

140

STAT

JANUARY 2, 2024

The first phone call came some time in late 1996. “Ed, I’d like to introduce myself. My name is Sid Wolfe of Public Citizen,” he said. “And I’ve got something for you.” He started out matter of fact, but spoke very quickly. To be honest, I can’t recall the subject anymore, but I do remember he peppered every sentence with lots of medical terminology.

FDA 140

FDA 140

Fierce Pharma

JANUARY 2, 2024

AbbVie is entering 2024 with a foothold in the antibody-drug conjugate (ADC) field thanks to its late-2023 buyout of ImmunoGen worth more than $10 billion. | According to a recent securities filing, AbbVie only entered the ImmunoGen bidding war after other buyout interest led the ADC specialist to widen its pool of potential purchasers. When it came down to the final three players, AbbVie's offer blew the others out of the water.

130

130

STAT

JANUARY 2, 2024

For all the flack they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers. But don’t take their numbers as gospel, experts warned. “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Econo

Hospitals 139

Hospitals Insurance 139

Pharmacy Times

JANUARY 2, 2024

Health coaches supporting remote pharmacist services can improve diabetes disparities.

121

121

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 2, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Power, politics, and care for the poor in Texas Local officials in Austin, Texas promised twelve years ago that if voters approved millions of dollars in new property taxes, it would be a win-win.

Medical Schools 121

Medical Schools Hospitals Insurance 121

Fierce Healthcare

JANUARY 2, 2024

Yet another notable payer-provider contract negotiation is going public. | In a statement, the health system said that the insurance giant underpays for its services compared to other providers in the region.

Insurance 119

Insurance 119

STAT

JANUARY 2, 2024

WASHINGTON — The Biden administration seemed to be giving pharmacies a win when they forced pharmacy benefit managers to be more up-front about the behind-the-scenes fees they charge. But now pharmacies are afraid the transition to the new system on Jan. 1 will lead to a cash flow crunch. In the past, PBMs could charge pharmacies performance-based fees long after the fact, and the total amount of the fees has grown in recent years.

120

120

pharmaphorum

JANUARY 2, 2024

Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine, its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding and can take another $100 million if an ongoing review of ensifentrine by the US FDA results in regulatory approval.

FDA 119

FDA 119

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JANUARY 2, 2024

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome. The negative study outcome was never in doubt , so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin.

120

120

Pharmacy Times

JANUARY 2, 2024

At a time when pharmacist burnout and turnover is higher than ever before, talent retention is increasingly a strategic imperative for hospitals.

Hospitals 118

Hospitals 118

STAT

JANUARY 2, 2024

AUSTIN, Texas — The partnership between one of the nation’s largest Catholic health systems and a local government agency focused on caring for poor patients was supposed to be mutually beneficial for everyone involved. But it didn’t quite turn out that way. The alliance in theory meant that Travis County, home to the growing metro area of Austin, could provide more care to low-income patients cheaper than other big cities in the state.

Medical Schools 117

Medical Schools Hospitals 117

Fierce Pharma

JANUARY 2, 2024

AstraZeneca and Sanofi have scored first in | AstraZeneca and Sanofi have scored first in China with an approval for their respiratory syncytial virus (RSV) immunization Beyfortus for infants, with the companies expecting the shot to be available there for the 2024-25 season. Beyfortus is the only immunization approved for babies entering their first RSV season to protect them against lower respiratory tract infection.

Immunization 117

Immunization 117

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Drug Topics

JANUARY 2, 2024

Higher concentrations of omega-3 fatty acids were associated with the ability to exchange carbon dioxide more efficiently and longer transplant-free survival.

112

112

Fierce Healthcare

JANUARY 2, 2024

BJC HealthCare of St. Louis and Saint Luke’s Health System of Kansas City have officially completed their cross-market deal to merge into a single integrated, academic nonprofit health system. | Under the new banner of BJC Health System, the Missouri-based nonprofit counts about $10 billion in revenue and $1 billion of anticipated community impact per year.

111

111

pharmaphorum

JANUARY 2, 2024

Novo Nordisk is planning to open an AI research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations

111

111

STAT

JANUARY 2, 2024

Is it too early to say that the health tech boom feels like a million years ago? In 2020 and 2021, the jolt of pandemic and favorable economic conditions created an explosion of adoption and investment for companies that hoped to transform some corner of the stodgy health care system with technology. Those roaring days feel like a distant memory. Many of those would-be disrupters are now struggling through a much different environment.

110

110

pharmaphorum

JANUARY 2, 2024

Astellas has licensed up to four macrophage enhancer drugs with potential as cancer immunotherapies from Elpiscience in a $1.

111

111

Drug Store News

JANUARY 2, 2024

Caroline Callaway, president and founder of Bolt PR, shares why the consumer product sector needs more women in C-Suite leadership roles.

106

106

European Pharmaceutical Review

JANUARY 2, 2024

A paper published in the European Journal of Pharmaceutics and Biopharmaceutics has reviewed the current application status of Quality by Design (QbD) within the framework of the ICH guidelines (ICH Q8(R2) – Q14 and ICH Q2(R2)). Over the past several years, the pharmaceutical industry has faced challenges regarding quality assurance in drug development, the author asserted.

Documentation 105

Documentation 105

The Checkup by Singlecare

JANUARY 2, 2024

From stress and caffeine withdrawal to genetic predisposition, there are loads of reasons why you might get a headache on a regular basis. But one often overlooked, but common cause is dehydration, even mild dehydration can cause headache pain. Here, learn how to determine if dehydration is contributing to your pain, plus steps you can take to manage symptoms and prevent them from recurring in the future.

105

105

Pharmaceutical Commerce

JANUARY 2, 2024

Agreement includes novel cell therapy for hematology that has the opportunity to bring a potential best-in-class treatment to patients with blood cancers.

105

105

Outsourcing Pharma

JANUARY 2, 2024

A Los Angeles clinic is holding a free webinar covering the facts and myths about ketamine following the death of late actor, Matthew Perry.

105

105

pharmaphorum

JANUARY 2, 2024

Shares in US biotech Anavex Life Sciences fell sharply this morning after Rett syndrome candidate Anavex 2-73 failed a phase 2/3 trial

104

104

STAT

JANUARY 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

103

103

pharmaphorum

JANUARY 2, 2024

Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, licensing candidates for Huntington's disease and SMA

103

103

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024. Inflation and geopolitical pressure The second biggest negative impact was thought to be geopolitical conflicts and inflation.

102

102

Pharmacy Times

JANUARY 2, 2024

Billions of samples are discarded while investigators struggle to assemble collections.

Hospitals 100

Hospitals 100